Carisma Therapeutics, Inc.

DB:W2J Stock Report

Market Cap: €16.0m

Carisma Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Steve Kelly

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage13.2%
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure1.6yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Kelly's remuneration changed compared to Carisma Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$461k

-US$87m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$80m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$666kUS$440k

-US$61m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$1mUS$416k

-US$41m

Compensation vs Market: Steve's total compensation ($USD3.50M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Kelly (59 yo)

1.8yrs

Tenure

US$3,504,425

Compensation

Mr. Steven Kelly, also known as Steve, is President, Chief Executive Officer and Director of Carisma Therapeutics, Inc. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Kelly
President1.8yrsUS$3.50mno data
Michael Klichinsky
Co-Founder & Chief Scientific Officer1.8yrsUS$1.60m1.16%
€ 185.9k
Richard Morris
CFO, Chief Compliance Officer1.8yrsUS$1.66m0%
€ 0
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Eric Siegel
General Counsel & Corporate Secretary1.5yrsno datano data
Terry Shields
Senior Vice President of Human Resources1.5yrsno datano data
Tom Wilton
Chief Business Officer4.9yrsno datano data
Eugene Kennedy
Chief Medical Officerless than a yearno datano data
Kenneth Locke
Senior Vice President of Technical Operationsless than a yearno datano data

1.6yrs

Average Tenure

52.5yo

Average Age

Experienced Management: W2J's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Kelly
President1.8yrsUS$3.50mno data
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Sanford Zweifach
Independent Chairman of the Board1.8yrsUS$271.55k0.00099%
€ 158.6
Hyam Levitsky
Member of Scientific Advisory Boardno datano datano data
Carl June
Member of Scientific Advisory Boardno datano datano data
Nina Bhardwaj
Member of Scientific Advisory Board4.4yrsno datano data
Briggs W. Morrison
Independent Director1.8yrsUS$220.20k0.029%
€ 4.7k
Marella Thorell
Directorless than a yearno datano data
John Hohneker
Independent Directorless than a yearno data0%
€ 0
Lisa Coussens
Member of Scientific Advisory Boardno datano datano data
Prasad Adusumilli
Member of Scientific Advisory Board4.4yrsno datano data
Lin Guey
Member of Scientific Advisory Board1.8yrsno datano data

1.8yrs

Average Tenure

64yo

Average Age

Experienced Board: W2J's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 00:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Justin ZelinBTIG
Naureen QuibriaCapital One Securities, Inc.